🟢 Marker Therapeutics is trading 6.1% up today after H.C. Wainwright reiterated its Buy rating

Marker Therapeutics is trading 6.1% up now at $1.29 after H.C. Wainwright reiterated its Buy rating and $10 price target on August 21, 2026.

• The analyst highlighted progress toward a potential 2026 pivotal lymphoma trial and expected FDA feedback.
• Upcoming MT-601 and APOLLO data remain in focus.
• No new company press release was identified; broader biotech-sector context remains supportive after recent oncology-news-driven interest.